ViroPharma Looks To Cinryze To Drive Sales As Vancocin Faces Likely Generic Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech's HAE drug exceeded sales expectations during the second quarter, but FDA cites the company for misleading promotion.